Current Report Filing (8-k)
04 June 2019 - 6:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
June 3, 2019
_____________________
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified in
its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 1608, New York, New
York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(212) 980-9155
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
TNXP
|
The NASDAQ Global Market
|
Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure.
|
The Company updated its investor presentations, which
are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends
to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibit 99.02, 99.03
and 99.04 hereto and incorporated herein by reference.
The information in this Item 7.01 of this Current Report
on Form 8-K, including Exhibits 99.02, 99.03 and 99.04 attached hereto, shall not be deemed “filed” for purposes of
Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
|
Exhibit
No.
|
|
Description.
|
|
|
|
|
|
99.01
99.02
99.03
|
|
Corporate Presentation by the Company for June
2019 (Long Form)
Corporate Presentation by the Company for June
2019 (Short Form)
Corporate Presentation by the Company for June
2019 (Abbreviated Form)
|
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING CORP.
|
|
|
|
By:
|
/s/ Bradley Saenger
|
|
|
Bradley Saenger
Chief Financial Officer
|
Date: June 3, 2019
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024